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Familial thyroid cancer has become a well-recognized entity in patients with thyroid cancer originating from follicular cells, that is,
nonmedullarythyroidcarcinoma.Thediagnosisoffamilialthyroidcancerprovidesanopportunityforearlydetectionandpossible
prevention in family members. Understanding the syndromes associated with familial thyroid cancer allows clinicians to evaluate
and treat patients for coexisting pathologic conditions. About ﬁve percents of patients with well-diﬀerentiated thyroid carcinoma
have a familial disease. Patients with familial non-medullalry thyroid cancer have more aggressive tumors with increased rates of
extrathyroidextension,lymphnodemetastases,andfrequentlyshowthephenomenonof“anticipation”(earlierageatdiseaseonset
and increased severity in successive generations). So far, four predisposition loci have been identiﬁed in relatively rare extended
pedigrees, and association studies have identiﬁed multiple predisposing variants for diﬀerentiated thyroid cancer. This suggests
that there is a high degree of genetic heterogeneity and that the development of this type of tumor is a multifactorial and complex
process in which predisposing genetic variants interact with a number of incompletely understood environmental risk factors.
Thus, the search for the causative variants is still open and will surely beneﬁt from the new technological approaches that have
been developed in recent years.
1. Thyroid Cancer:Epidemiology and
Clinicopathologic Features
Thyroid cancer is divided into two types, based on the
cells of origin: diﬀerentiated thyroid cancer of follicular
cell origin (NMTC) and medullary thyroid cancer (MTC)
originating from parafollicular cells [1]. The molecular
mechanisms underlying MTC development, mainly due to
gain-of-function mutations of the proto-oncogene RET have
been studied in depth and are out of the scope of this
work. Readers are referred to [2] for an updated review
of the subject. Thyroid cancer is the most common form
of neoplasia of the endocrine system, accounting for about
1%–3% of all cancers, with an annual incidence in various
parts of the world ranging from 0.5–10 per 100000 [3].
The incidence of thyroid cancer is increasing, with one of
the fastest rates of increase among common human cancers.
Today, non-medullary thyroid cancer is the seventh most
common tumor in women [4]. Improvement in cancer
diagnosis can partly explain the phenomenon. However,
early diagnosis alone is unlikely to account for this increase,
and environmental factors must also play a role [5]. Several
risk factors have been identiﬁed for thyroid carcinoma, such
as radiation exposure, iodine deﬁciency and excess, and pre-
vious history of benign thyroid disease, such as nodules and
autoimmune thyroid diseases. NMTC also has a signiﬁcant
gender bias, with a ratio of aﬀected women : men of 2.6 : 1
[6], suggesting that the hormonal environment may play an
important role. The vast majority of patients with sporadic
NMTC have well-diﬀerentiated tumors, papillarythyroid
carcinoma (PTC), or follicular thyroid carcinoma (FTC).
Papillarythyroidcarcinomaaccountsforapproximately80%
of NMTC and is characterized by distinctive nuclear alter-
ations including pseudoinclusions, grooves, and chromatin
clearing.PTCs smaller than1cm are referred to as papillary
microcarcinomas [7]. These tumors have been identiﬁed in2 Journal of Oncology
Table 1: Familial syndromes with associated non-medullary thyroid cancer.
Syndrome Clinical Features Inheritance pattern Locus Gene
Gardner’s
syndrome (FAP)
gastrointestinal adenomatous polyps,
osteomas, epidermoid cysts, hypertrophy
of the retinal epithelium, desmoid
tumors, PTC (cribiform-morular variant)
Autosomal dominant 5q21 APC
Cowden disease hamartoma, breast cancer, PTC, FTC Autosomal dominant 10q22 PTEN
Carney complex pituitary, gonadal, and adrenal gland
cancer, PTC, FTC Autosomal dominant 17q23-24 PRKAR1a
Werner
syndrome
Premature aging, soft tissue sarcomas,
osteosarcoma, FTC/PTC Autosomal recessive 8p11-p12 WRN
up to 35% of individuals at autopsy, suggesting that they
may be extremely common, although they rarely become
clinically relevant. PTC can be also multifocal but is typically
slow growing, with a tendency to spread to lymph nodes and
usuallyhasanexcellentprognosis.Activationofthemitogen-
activated protein kinase (MAPK) pathway as a result of
mutually exclusive BRAF or RAS mutations or of somatic
recombinationofRET(RET/PTCrearrangement)orNTRK1
(TRK rearrangement) genes is found in the majority of
PTCs [8, 9]. Follicular thyroid carcinoma accounts for
approximately 15% of NMTC and is deﬁned by its invasive
features that result in inﬁltration of blood vessels and/or
full penetration of the tumor capsule, in the absence of
the nuclear alterations of papillary carcinoma. FTC is rarely
multifocaldoesnotusuallymetastasizetotheregionallymph
nodesbuttendstospreadviathebloodstreamtothelungand
bones. An important histologic variant of FTC is the onco-
cytic(H¨ urthlecell,oxyphilic)follicularcarcinomacomposed
of eosinophilic cells repleted with mitochondria. Activating
mutations of RAS genes, activation of the PTEN/AKT
pathway (due to activating mutations of PIK3CA or loss-of-
function mutations of PTEN) [10, 11], or rearrangements
of the genes PAX8 and PPAR γon chromosome 2q24 are
often found in sporadic FTC [12]. The least common form
of NMTC, accounting for less than 5% of cases, is poorly
diﬀerentiated and anaplastic (undiﬀerentiated) thyroid car-
cinomas, the latter representing one of the most lethal forms
of human tumors. Mutations in the tumor suppressor gene
p53 are typically identiﬁed in this type of carcinoma [13].
2.FamilialSyndromes
Several syndromes are associated with non-medullary thy-
roid cancer such as Gardner’s syndrome (familial adeno-
matous polyposis, FAP), Cowden disease (multiple hamar-
toma), Carney complex, and Werner syndrome. A summary
of the clinical features and genes involved (when known)
in familial syndromes associated with thyroid cancer is
reported in Table 1 [14]. Gardner’s syndrome or FAP results
from loss-of-function mutations in the APC (adenomatous
polyposis coli) tumor-suppressor gene on chromosome
5q21 and is associated with gastrointestinal adenomatous
polyps, osteomas, epidermoid cysts, congenital hypertrophy
of the retinal epithelium, desmoid tumors, and thyroid
cancer. FAP is associated with a “cribiform-morular variant”
of PTC, so called because of its unique histopathologic
features. However, fewer than 2% of patients with FAP
develop PTC, suggesting that PTC development is probably
related to increased susceptibility rather than a speciﬁc
mutation. Cowden disease, also known as “multiple hamar-
toma syndrome,” is associated with an increased risk of
developing both benign and malignant breast tumors, and
well-diﬀerentiatedthyroidtumors.Eightypercentofpatients
have germline mutations of the PTEN (phosphatase and
tensin homologue) tumor-suppressor gene. Carney complex
involves both endocrine and nonendocrine organs and
can aﬀect pituitary, thyroid, gonadal, and adrenal glands.
Both PTC and FTC have been associated with Carney
complex type 1. The adrenal gland pathology includes a
primary pigmented micronodular hyperplasia, which is the
only known familial cause of adrenal Cushing’s syndrome,
and additional pathologies include myxomas, nevi, and
schwannomas. Carney complex type 1 is associated with a
mutation in the PPRKAR1α (protein kinase A regulatory
subunit type 1-alpha) gene. Werner syndrome is a disease
of connective tissue characterized by premature aging and is
often referred to as “progeria.” Patients have a predisposition
to cancer, notably soft tissue sarcomas, osteosarcoma, and
thyroidcancer(FTCandalsoPTC)whichmaydevelopasthe
result of genomic instability. Mutations in the RecQ helicase
WRN gene have been identiﬁed, but the exact role of WRN
is not known. It is possible that RecQ helicase acts as a tumor
suppressor and may be responsible for genome stability.
3. FamilialNonmedullaryThyroid
Carcinoma(FNMTC): RiskFactorsand
GeneticPredisposition
Patients with familial NMTC may have more aggressive
tumorswithincreasedratesofextrathyroidextension,lymph
node metastases, and larger tumors in younger patients
[4], underscoring the importance of accurate diagnosis.
Establishing the diagnosis of a familial thyroid carcinoma
may provide the opportunity for its early identiﬁcation
and possible prevention in family members. About 5%
of patients who have well-diﬀerentiated thyroid carcinoma
show a familial occurrence. The clinico-pathological features
included in the analysis on familial NMTC are as reported in
[15]; the mean tumor size in familial PTC/FTC is ∼1.7cmJournal of Oncology 3
diameter. When the primary cancer site is considered in
epidemiological studies, the thyroid gland shows the highest
estimate of familial relative risk among all organs (between
5 and 10.4 folds as compared to ∼1.8 and 2.7 for breast
and colon cancer, resp., [16]). This indicates the presence of
a strongly inherited component of the disease [6, 16, 17].
As for all diseases, the identiﬁcation of a relevant familial
recurrence risk in NMTC is complicated by the argument
that families share the same environment as well as a
common genetic background and it is therefore diﬃcult to
distinguish between environmental and genetic contributing
factors. Although the initial familial aggregations reported
over a period of time were seen as chance occurrences
due to a shared environment, familial occurrence has more
recently been recognized as a signiﬁcant risk factor in NMTC
[18]. Since the ﬁrst observation of a familial case of PTC
by Robinson and Orr [19] who reported PTC in twins, a
number of pedigrees have been identiﬁed. It has been esti-
matedthatafamilywiththreeaﬀectedmemberswithclinical
NMTC due to environmental causes would occur by chance
less than once in every 100 years. Therefore, the existence
of pedigree collections of the size presented by Lesueur et
al. [20] cannot occur by chance, but rather are associated
with inherited predisposition. Similarly, Malchoﬀ et al.,
who presented a large pedigree with PTC with 5 clinically
signiﬁcant cases, noted that the chance of 5 PTC occurring
in a family of 23 individuals by chance would be 1 in two
billion [21]. A population-based study in Norway of 5673
patients who had a ﬁrst-degree relative with an index thyroid
cancer, conﬁrmed that these patients had an increased risk
of developing thyroid cancer [22]. The incidence of PTC,
primary pigmented nodular adrenocortical disease, and its
associated conditions increased sixfold in men and fourfold
in women if a ﬁrst-degree relative had NMTC. Patients who
havetwoﬁrstdegreerelativeswithwell-diﬀerentiatedthyroid
cancer and do not have a familial syndrome are currently
classiﬁed as having familial NMTC [23]. Those who have
more than two direct relatives with FNMTC have a decreased
survival compared with patients who have one or two
aﬀecteddirectrelatives[14].Inordertodiﬀerentiatebetween
FNMTC and familial syndromes associated with thyroid
cancer, it is important to detect extra-thyroidal disease in
patients aﬀected with a familial syndrome. Patients who have
familial NMTC have more aggressive tumors with increased
rates of extra-thyroid extension, lymph node metastases,
and larger tumors in younger patients. A recent work by
Capezzone et al. compared the features of patients with
sporadic and familial NMTC patients and tested whether
FNMTC patients with parent-child relationship exhibit an
“anticipation” phenomenon (earlier age at disease onset and
increased severity in successive generations) [15]. In fact,
signiﬁcant diﬀerences between sporadic PTC and FNMTC
patients included more frequent tumor multifocality (P =
.001) and worse ﬁnal outcome in FNMTC patients (P =
.001). In addition, among FNMTC cases with parent-child
relationships, an earlier age at disease presentation (P<
.0001), diagnosis (P<. 0001), and disease onset (P = .04)
were found in the second generation when compared with
the ﬁrst generation. Patients in the second generation had a
higher rate of lymph node metastases at surgery and worse
outcome when compared with the ﬁrst generation.
4.FamilialRisk inFNMTC
Considering these ﬁndings, NMTC does appear to be an
inheritedtrait.TheprevalenceofFNMTChasbeenestimated
to be between 2.5% and 8% of the total NMTC patients.
The majority of FNMTC pedigrees are small [20]; the
pattern of inheritance is usually autosomal dominant, but
since a large number of pedigrees present a signiﬁcant
lack of penetrance, polygenic inheritance cannot be ruled
out [20, 24]. The variable expression of FNMTC suggests
that the responsible gene(s) may lead to predisposition
or susceptibility to thyroid cancer. In addition to NMTC,
members of FNMTC pedigrees may present a spectrum of
benign thyroid diseases including follicular adenoma, diﬀuse
and multinodular goitre, and autoimmume thyroiditis. As
mentioned above, these diseases are considerably more
common in the general population than NMTC. However,
the high occurrence of these diseases in FNMTC pedigrees
suggests that they are a part of FNMTC, and pedigree
members are therefore considered to be at increased risk of
benign thyroid disease [18, 23].
5.FNMTC SusceptibilityLoci
Inordertoidentifythegene(s)responsibleforthyroidcancer
predisposition,severalgroupshaveundertakengenomewide
linkage analysis using microsatellite markers evenly dis-
tributed across the genome and informative large pedigrees
with multiple aﬀected members. To date, four diﬀerent loci
have been identiﬁed for genetic predisposition to familial
NMTC. The ﬁrst locus to be implicated in familial PTC was
MNG1, which maps to chromosome 14q31. In this case,
the authors studied a family from Montreal, Canada, with
18 aﬀected with multinodular goitre (MNG), two of whom
presented with PTC and one with follicular adenoma. The
predisposing locus was identiﬁed by linkage analysis with a
maximal LOD (Logarithm Of Odds, a genetic measure of
the signiﬁcance of linkage) score of 4.88distal to marker
D14S1030,theregionofinterestspanningaround1Mb[25].
The locus was conﬁrmed in other families with MNG [26],
but no evidence of linkage was found in additional FNMTC
pedigrees suggesting that only a small percentage of FNMTC
can be attributed to this locus [20, 27]. A second locus,
PRN1, was identiﬁed by Malchoﬀ et al. on chromosome
1q21 in an American family with ﬁve members aﬀected
by PTC, one by colon cancer and two by papillary renal
carcinoma [28]. The susceptibility locus was identiﬁed at
1q21 with a maximum LOD score of 3.58 in a critical
region of 20cM This region encompasses the NTRK1 gene,
but no mutation segregating with the disease was found
among FNMTC pedigrees [27]. To date, linkage to this locus
has not been conﬁrmed in any other independent study.
The existence of a susceptibility locus for familial NMTC
(NMTC1)onchromosome2q21wasﬁrstidentiﬁedinalarge
Tasmanian pedigree with recurrence of papillary thyroid4 Journal of Oncology
carcinoma (PTC) [29]. In the same study, linkage analysis
of 80FNMTC pedigrees gave a signiﬁcant LOD score of
3.07 at marker D2S2271. Stratiﬁcation based on the presence
of at least one case of the follicular variant of PTC, the
phenotype observed in the Tasmanian family increased the
correspondingLODscoreforchromosome2,suggestingthat
thislocusmaybestrictlycorrelatedtothefollicularvariantof
PTC. Finally, the fourth susceptibility locus is TCO (Thyroid
Carcinoma with Cell Oxyphilia) mapped on chromosome
19p13.2 by Canzian et al. [30]. The study analysed a large
French pedigree with six patients aﬀected by MNG and
three by PTC. A review of the histology indicated that
all cases examined presented oncocytic features. Oncocytic
tumors, also known as oxyphilic tumors and in the thyroid
gland as H¨ urthle cell tumors, are made of cells replete
with mitochondria with a “swollen” (i.e., “oncocytic,” from
the Greek word onkoustai, to swell) appearance. Oncocytic
tumors may occur at various sites (see [31], for a review)
but they are more frequently observed in the thyroid gland.
Thyroid oncocytic tumors originate from follicular cells,
with the exception of the rare oncocytic variant of medullary
carcinoma. They can be benign (oncocytic adenomas) or
malignant (oncocytic carcinomas). Oncocytic tumors in the
thyroid are regarded as special subtypes, since their features
are distinct enough to set them apart from corresponding
neoplasms lacking mitochondrial accumulation. Accord-
ingly, oncocytic thyroid carcinomas are classiﬁed as variants
of FTC (more commonly) or of PTC (less commonly) [1].
Using this distinctive phenotype for data analysis led to the
successful identiﬁcation of a predisposing locus for thyroid
cancer with oncocytic features on chromosome 19p13.2,
with a signiﬁcant LOD score at marker D19S916 (3.01).
The TCO locus extends up to ∼2Mb and has been further
reﬁned to a 1.6Mb interval by adding more markers and
more families with aﬀected individuals showing oncocytic
tumors [32]. It is worth noting that linkage to the TCO locus
has been subsequently conﬁrmed in independent studies
[18, 27]. Furthermore, analysis of additional families has
provided evidence for the genetic interaction between the
TCO at 19p13 and NMTC1 at 2q21 loci, resulting in a
signiﬁcantly increased risk of NMTC in patients that carry
both susceptibility loci [32] .S e v e r a lg r o u p sh a v eu n d e r -
taken a positional candidate gene approach to identify the
causative mutation underlying TCO predisposition, taking
into account the speciﬁc phenotype of thyroid oncocytic
tumors, that is, the abnormal proliferation of mitochondria
and the presence of a severe bioenergetic defect [33–37].
Our group recently deﬁned the bioenergetic defect in vitro
in the only existing thyroid oncocytic tumor cell model,
the XTC.UC1 cell line. Two mutations were identiﬁed in
mitochondrial DNA (mtDNA) which aﬀect complex I and
III of the OXPHOS respiratory chain [38]. One of the
mutations is a single base pair insertion in the ND1 complex
I gene, causing a premature stop codon and the absence
of the protein as evaluated by western blot analysis. The
second is a missense mutation in the CYTB complex III
gene. These two mutations markedly decrease the activity of
both respiratory complexes and explain the defective ATP
synthesis previously reported [33, 34]. Subsequently, the
high occurrence of pathogenic mutations impairing complex
I has been conﬁrmed by our group in vivo in sporadic
thyroid oncocytic tumors, leading to the conclusion that
disruptive complex I mutations may well be considered to
be the hallmarks of the oncocytic phenotype [39]. The close
association between disruptive complex I mutations and the
oncocytic phenotype has also been conﬁrmed in other types
of oncocytic tumors [40–43]. Since the human complex I
is composed of 45subunits, only 7 of which are mtDNA-
encoded, our search for the defective nuclear gene on chro-
mosome 19p13.2 began with the analysis of genes encoding
mitochondrial complex I subunits and mapping to the TCO
locus. So far, somatic and germline missense mutations have
been reported in the NDUFA13 gene (previously known as
GRIM19) [44], a member of complex I and a key regulator
of cell death. Germline mutations have been reported by
our group in TIMM44, a component of the mitochondrial
translocon complex for importing nuclear-encoded proteins
into the mitochondria [45]. However, the eﬀect of these
mutations in TCO predisposition is still uncertain, since
either no functional studies have been presented (at least for
NDUFA13) or they did not reveal a clear negative eﬀect in
functional molecular studies [45]. Moreover, the family in
which the locus was originally mapped [30] did not carry
any coding mutation in NDUFA13 and TIMM44, suggesting
either that these genes are not directly involved in the TCO
etiology or at least the presence of genetic heterogeneity in
TCO. Several other genes mapping to the region encode
proteins involved in mitochondrial functions and/or with
a known role in tumor development, and these have been
subsequently screened. A list of all the genes so far analysed
without identifying etiological variants is reported in Table 2
(our unpublished results). Thus, the search for the TCO
predisposing variants is still open. The application of next-
generation sequencing technologies capable of sequencing of
∼2 megabases of genomic DNA in a single experiment, will
allow the entire TCO region to be resequenced, and not just
thecodingregionofgenes,alimitofthetraditionalcandidate
geneapproach.Identiﬁcationoftherelevantmutation(s)will
surely beneﬁt the characterization of TCO.
6. AssociationStudiesinThyroid Cancer
FNMTC has been identiﬁed as a clinically distinct entity
from its sporadic counterpart, and although the mutated
genes(s) have not yet been identiﬁed, the genetic basis
underlying its predisposition has been recognized by the
scientiﬁc community. However, several studies have recently
reported the identiﬁcation of predisposing common vari-
ants in association-based case-control studies using single
nucleotide polymorphism (SNP) high throughput genotyp-
ing [46–49]. One of the most signiﬁcant studies was a
genome-wide association scan in a large cohort of Icelandic
cases with thyroid cancer and respective controls, followed
by a replication study in individuals of European descent
[49]. The authors demonstrated that two common variants,
located on 9q22.33 and 14q13.3, are associated with the dis-
ease. Overall, the strongest association signals were observed
for rs965513 on 9q22.33 (OR = 1.75; P = 1.7 × 10
−27)Journal of Oncology 5
Table 2: New changes in cDNA of TCO candidate genes on 19p13.2.
PCR product Change in cDNA Type of aa
change
Het frequency in
TCO patients (%)
Het frequency in
controls (%)
TIMM44x4 G344A C925A silent P308Q 12.5 12.5 na 0 0 na na
TIMM44x9 G1274A G509A silent silent 12.5 12.5 na na 22.5 3.0
TIMM44x13 T971C G868T silent 3 UTR 12.5 12.5 8.0 na na na na
ELAVL1x3 C591A G1111C silent R219P 42.9 13.0 25.0 14.2 na na na na
ELAVL1x5 Δ(CTTCCACTTCA 3 UTR 5 UTR 12.5 12.5 na na na na
CCL25x5 AC) bp1267-1280 T289M 37.5 50.0 37.5 50.0 na na 7.3 na na
LASS1x3 C182T A866T K1266N 37.5 37.5
MARCH2x5 A3798C C4996T silent Y1897D 37.5 12.5 37.5 37.5
MARCH2x5 T5692G G9569C S3189T 12.5 50.0
GRIM19x1 A21814G T21858A I7271V silent 12.5
EDG5x2 G26790A C25572T silent silent
MUC16x1 T25638G A27791C D8546E
MUC16x1 C31905T G31721A N9263T
MUC16x1 G36955A G39400A silent R10573H
MUC16x2 C41705T E12318L
MUC16x3 V13133M
MUC163x P13901L
MUC16x3
MUC16x3
MUC16x3
MUC16x3
MUC16x5
MUC16x5
MUC16x15
MUC16x39
MUC16x63
na= not available. The changes cosegregating are reported. Only for TIMM44 missense change, the variant was not found in a large group of controls.
The other genes screened so far but with no new changes identiﬁed are NDUFA7, PPAN, FBLX12, ICAM1, ICAM4, LASS1, LASS4, SMARCA4, DNM2,a n d
ANGPL4; RAB11B; ADAMTS10; PIN1; UBL5; and KEAP1.
and rs944289 on 14q13.3 (OR = 1.37; P = 2.0 × 10
−9).
The gene closest to the 9q22.33 locus is FOXE1 (TTF2), and
NKX2-1 (TTF1) is among the genes located at the 14q13.3
locus. Both variants contributed to an increased risk of both
papillary and follicular thyroid cancer. Approximately 3.7%
of individuals were homozygous for both variants, and their
estimatedriskofthyroidcancerwas5.7-foldgreaterthanthat
of noncarriers. In a study using a large sample set from the
general population, both risk alleles are associated with low
concentrations of thyroid stimulating hormone (TSH), and
the 9q22.33 allele was associated with low concentration of
thyroxin (T(4)) and high concentration of triiodothyronine
(T(3)). Another interesting study, although not speciﬁc
for thyroid cancer as such, in an isolated population of
Sardiniansidentiﬁedastrongassociation(P = 1.3 × 10
−11)
between rs4704397 and circulating TSH levels [48]. Serum
TSH is a sensitive indicator of thyroid function, and overt
abnormalitiesinthyroidfunctionleadtocommonendocrine
disorders. Each additional copy of the minor A allele was
associated with an increase in TSH. The marker is located in
intron 1 of PDE8B, encoding a high-aﬃnity cAMP-speciﬁc
phosphodiesterase. The association was replicated in genet-
ically distant cohorts from Tuscany and Old Order Amish
(overall P value = 1.9 × 10
−20). It will be very interesting
to analyse the association of the above-mentioned SNPs with
the familial form of non-medullary thyroid carcinoma.
7. Conclusions
Familial NMTC represents 3%–7% of all thyroid tumors
and is associated with some of the highest familial risks
among all cancers, with a risk of developing this type of
neoplasia for ﬁrst-degree relatives of 5–10-fold compared to
the general population. Several predisposing loci have been
identiﬁed in the recent years but the mutated gene has not
been identiﬁed yet. However, the new technologies already
available have rendered the resequencing of large genomic
regions from deﬁned linkage intervals reasonably possible in
singleexperiments,andtheapplicationofthesemethodswill
greatly speed up the search for the NMTC gene(s). It will
then become possible for NMTC families to receive careful
genetic counseling for all at-risk members similarly to what6 Journal of Oncology
is already happening for FMTC. In addition, the study of
FNMTC genetics, and in particular familial TCO represents
a key model for the study of nuclear and mitochondrial
crosstalkinthyroidtumordevelopment.Thethyroidglandis
characterizedbyahighenergeticmetabolismandanygenetic
defect (either of nuclear or mitochondrial origin) leading to
bioenergeticdeﬁcitsmayleadtoanalterationofthiscrosstalk
and to an alteration of the mitochondrial phenotype, as seen
inTCO.Identifyingthecausativemutationsinvolvedinthese
energetic defects will also provide a powerful tool to design
new and speciﬁc treatments for such tumors.
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